| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a homobifunctional linker, Bis-PEG4-TFP ester itself has no intrinsic biological activity; it serves as a structural connector to join two identical ligands (e.g., two target protein ligands or two E3 ubiquitin ligase ligands) in the synthesis of PROTAC molecules or other bioconjugates. The TFP ester groups are highly reactive toward primary amines, allowing for the formation of stable amide bonds under mild, aqueous-compatible conditions. TFP esters are known to be more stable than succinimidyl (NHS) esters in aqueous solutions, making them particularly suitable for protein and peptide conjugations where hydrolysis is a concern. The 4-unit PEG spacer (PEG4) provides flexibility and water solubility, reducing steric hindrance and improving the aqueous solubility of the final conjugate. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final conjugate after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95-98%. The TFP ester groups can be characterized by their characteristic chemical shifts in NMR spectroscopy (e.g., the fluorine atoms give signals in 19F NMR). The PEG4 spacer can be characterized by mass spectrometry. The IUPAC name is bis(2,3,5,6-tetrafluorophenyl) 3,3′-((oxybis(ethane-2,1-diyl))bis(oxy))dipropanoate.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical protocol, the TFP ester groups are reacted with primary amine-containing ligands (e.g., target protein ligands or E3 ligase ligands) in a buffer such as PBS (pH 7.4) at room temperature for 1-2 hours. The resulting conjugate is then purified and tested in cells for its biological activity. For PROTAC applications, the conjugate would be tested for target degradation. The PEG4 spacer improves water solubility of the reactants, facilitating the reactions in aqueous systems.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated using a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via intraperitoneal (IP) or intravenous (IV) injection. The PEG4 spacer may improve the pharmacokinetic properties of the conjugate by enhancing water solubility and reducing aggregation.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of approximately 590.41, a molecular formula of C24H22F8O8, and a standard purity of ≥95-98%. It appears as a solid at room temperature. For storage, it should be kept long-term in a cool, dry place, sealed, away from moisture. It is soluble in DMSO and other organic solvents. The product should be protected from light. The IUPAC name is bis(2,3,5,6-tetrafluorophenyl) 3,3′-((oxybis(ethane-2,1-diyl))bis(oxy))dipropanoate. CAS: 1446282-42-3.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The TFP ester groups are moisture-sensitive and should be handled in a dry environment. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license. This compound is not an approved drug and has not been cleared for clinical use.
|
| References |
[1]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.
|
| Additional Infomation |
The homobifunctional nature of Bis-PEG4-TFP ester allows for the synthesis of symmetric PROTAC molecules (where both ends are conjugated to the same type of ligand, e.g., a homodimeric PROTAC) or the crosslinking of two identical biomolecules. The TFP ester groups offer greater stability in aqueous solutions compared to NHS esters, reducing side reactions and improving conjugation yields, especially for protein-based conjugations. The PEG4 spacer provides a flexible, hydrophilic linker that balances water solubility and minimal steric hindrance for many PROTAC applications. This linker is also known as TFP-PEG4-TFP and is widely used in bioconjugation, surface functionalization, and the development of targeted therapeutics and diagnostics.
|
| Molecular Formula |
C24H22F8O8
|
|---|---|
| Molecular Weight |
590.41
|
| Exact Mass |
590.118
|
| CAS # |
1446282-42-3
|
| PubChem CID |
77078378
|
| Appearance |
Colorless to light yellow liquid（Density：1.416±0.06 g/cm3）
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
572.7±50.0 °C at 760 mmHg
|
| Flash Point |
289.0±25.0 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.474
|
| LogP |
3.76
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
40
|
| Complexity |
668
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C(=C(C(=C1F)F)OC(=O)CCOCCOCCOCCOCCC(=O)OC2=C(C(=CC(=C2F)F)F)F)F)F
|
| InChi Key |
QKJYOLJOWDJZRB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H22F8O8/c25-13-11-14(26)20(30)23(19(13)29)39-17(33)1-3-35-5-7-37-9-10-38-8-6-36-4-2-18(34)40-24-21(31)15(27)12-16(28)22(24)32/h11-12H,1-10H2
|
| Chemical Name |
(2,3,5,6-tetrafluorophenyl) 3-[2-[2-[2-[3-oxo-3-(2,3,5,6-tetrafluorophenoxy)propoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6937 mL | 8.4687 mL | 16.9374 mL | |
| 5 mM | 0.3387 mL | 1.6937 mL | 3.3875 mL | |
| 10 mM | 0.1694 mL | 0.8469 mL | 1.6937 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
